Search Results - "Quirt, Ian"

Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review by Quirt, Ian, Verma, Shailendra, Petrella, Teresa, Bak, Kate, Charette, Manya

“…Background. This systematic review examines the role of temozolomide in patients with metastatic melanoma. Outcomes of interest include response rate,…”
Get full text

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma by Verma, Shailendra, Quirt, Ian, McCready, David, Bak, Kate, Charette, Manya, Iscoe, Neill

“…The authors examined the role of systemic adjuvant therapy in patients with high‐risk, resected, primary melanoma. Outcomes of interest included overall…”
Get full text

Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs) by Nguyen, Linh T, Yen, Pei Hua, Nie, Jessica, Liadis, Nicole, Ghazarian, Danny, Al-Habeeb, Ayman, Easson, Alexandra, Leong, Wey, Lipa, Joan, McCready, David, Reedijk, Michael, Hogg, David, Joshua, Anthony M, Quirt, Ian, Messner, Hans, Shaw, Patricia, Crump, Michael, Sharon, Eran, Ohashi, Pamela S

“…Various immunotherapeutic strategies for cancer are aimed at augmenting the T cell response against tumor cells. Adoptive cell therapy (ACT), where T cells are…”
Get full text

Phase II study of marimastat (BB-2516) in malignant melanoma: A clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group by QUIRT, Ian, BODURTHA, Audley, LOHMANN, Reinhard, RUSTHOVEN, James, BELANGER, Karl, YOUNG, Vincent, WAINMAN, Nancy, STEWARD, William, EISENHAUER, Elizabeth

“…To determine the tolerability and efficacy of daily oral marimastat (BB-2516 in patients with metastatic melanoma and to determine the matrix metalloproteinase…”
Get full text

CCI‐779 in metastatic melanoma by Margolin, Kim, Longmate, Jeffrey, Baratta, Tracey, Synold, Tim, Christensen, Scott, Weber, Jeffrey, Gajewski, Thomas, Quirt, Ian, Doroshow, James H.

“…BACKGROUND CCI‐779 is an analog of the immunosuppressive agent, rapamycin, that has demonstrated activity against melanoma in preclinical models and shown…”
Get full text

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma by Hodi, F. Stephen, O'Day, Steven J, McDermott, David F, Weber, Robert W, Weber, Jeffrey S, Sosman, Jeffrey A, Haanen, John B, Gonzalez, Rene, Robert, Caroline, Schadendorf, Dirk, Hassel, Jessica C, Akerley, Wallace, van den Eertwegh, Alfons J.M, Lutzky, Jose, Lorigan, Paul, Vaubel, Julia M, Linette, Gerald P, Hogg, David, Ottensmeier, Christian H, Lebbé, Celeste, Peschel, Christian, Quirt, Ian, Clark, Joseph I, Wolchok, Jedd D, Tian, Jason, Yellin, Michael J, Nichol, Geoffrey M, Hoos, Axel, Urba, Walter J

“…The authors treated 676 patients with metastatic melanoma with an antibody to CTLA-4 (ipilimumab), the antibody plus a gp100 vaccine, or the vaccine alone…”
Get full text

Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience by Nicholas, Mathew N, Khoja, Leila, Atenafu, Eshetu G, Hogg, David, Quirt, Ian, Butler, Marcus, Joshua, Anthony M

“…Metastatic uveal melanoma (MUM) has a poor prognosis, with no established standard of care. Delineation of prognostic factors in MUM patients may enable…”
Get full text

Prognosticators of first line treatment for metastatic uveal melanoma (MUM) by Nicholas, Mathew, Khoja, Leila, Hogg, David, Quirt, Ian, Butler, Marcus O., Joshua, Anthony M.

“…Abstract only…”
Get full text

CCI-779 in metastatic melanoma : A phase II trial of the california cancer consortium by MARGOLIN, Kim, LONGMATE, Jeffrey, BARATTA, Tracey, SYNOLD, Tim, CHRISTENSEN, Scott, WEBER, Jeffrey, GAJEWSKI, Thomas, QUIRT, Ian, DOROSHOW, James H

“…CCI-779 is an analog of the immunosuppressive agent, rapamycin, that has demonstrated activity against melanoma in preclinical models and shown clinical…”
Get full text

Pyruvate Kinase Deficiency and Malaria by Ayi, Kodjo, Min-Oo, Gundula, Serghides, Lena, Crockett, Maryanne, Kirby-Allen, Melanie, Quirt, Ian, Gros, Philippe, Kain, Kevin C

“…Erythrocytes from patients with pyruvate kinase deficiency are resistant to invasion by Plasmodium falciparum . Such erythrocytes that succumb to infection are…”
Get full text

A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma by McWhirter, Elaine, Quirt, Ian, Gajewski, Thomas, Pond, Gregory, Wang, Lisa, Hui, June, Oza, Amit

“…Summary Purpose A two stage multi-institution Phase II study was undertaken by the Princess Margaret Hospital Consortium to evaluate the efficacy and toxicity…”
Get full text

The real cost of iron chelation therapy by Pavenski, Katerina, Quirt, Ian

Get full text

Escalated as Compared with Standard Doses of Doxorubicin in BACOP Therapy for Patients with Non-Hodgkin's Lymphoma by Meyer, Ralph M, Quirt, Ian C, Skillings, Jamey R, Cripps, M.C, Bramwell, Vivien, Weinerman, Brian H, Gospodarowicz, Mary K, Burns, Bruce F, Sargeant, Ann Marie, Shepherd, Lois E, Zee, Benny, Hryniuk, William M

“…In treating patients with cancer, the dose intensity of chemotherapeutic drugs, defined as the dose of drug per unit of time, may be a determinant of their…”
Get full text

Erythropoiesis-stimulating agents (ESAs): Do they still have a role in chemotherapy-induced anemia (CIA)? by Bormanis, Janis, Quirt, Ian, Chang, José, Kouroukis, C. Tom, MacDonald, David, Melosky, Barb, Verma, Sunil, Couture, Felix

“…Abstract Purpose Anemia in cancer patients can be a result of the underlying cancer or related to treatment. Erythropoiesis-stimulating agents (ESAs) are an…”
Get full text

Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries by Wainstein, Alberto, Algarra, Salvador Martin, Bastholt, Lars, Cinat, Gabriela, Demidov, Lev, Grob, Jean Jacques, Guo, Jun, Hersey, Peter, Espinosa, Enrique, Schachter, Jacob, Whitaker, Dagmar, Quirt, Ian, Hauschild, Axel, Rutkowski, Piotr

“…Risk factors for melanoma are well known and have guided plans for primary and secondary prevention. The presentation of the disease, however, varies widely…”
Get full text

Intravenous iron and recombinant erythropoietin for the treatment of postoperative anemia by KARKOUTI, Keyvan, MCCLUSKEY, Stuart A, GHANNAM, Mohammed, SALPETER, Mary-Jane, QUIRT, Ian, YAU, Terrence M

“…To determine if early recovery from severe post-operative anemia is accelerated by iv iron therapy alone or in combination with recombinant erythropoietin…”
Get full text

Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha by Humphreys, Michael Robert, Cino, Maria, Quirt, Ian, Barth, David, Kukreti, Vishal

Get full text

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma by Burdette-Radoux, Susan, Tozer, Richard G, Lohmann, Reinhard C, Quirt, Ian, Ernst, D Scott, Walsh, Wendy, Wainman, Nancy, Colevas, A Dimitrios, Eisenhauer, Elizabeth A

“…To test the activity of the cyclin dependent kinase (cdk) inhibitor flavopiridol in malignant melanoma, a disease with frequent abnormalities of the cyclin…”
Get full text

Pyruvate Kinase Deficiency and MalariaBrief Report by Ayi, Kodjo, Min-Oo, Gundula, Serghides, Lena, Crockett, Maryanne, Kirby-Allen, Melanie, Quirt, Ian, Gros, Philippe, Kain, Kevin C

“…Malaria that is caused by Plasmodium falciparum is a significant global health problem. Genetic characteristics of the host influence the severity of disease…”
Get full text

Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review by Petrella, Teresa, Quirt, Ian, Verma, Shailendra, Haynes, Adam E, Charette, Manya, Bak, Kate

“…Summary Background The aim of this systematic review was to determine the role of single-agent interleukin-2 in the treatment of adults with metastatic…”
Get full text